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ARTICLE
Recurrent De Novo Dominant Mutations in SLC25A4
Cause Severe Early-Onset Mitochondrial Disease
and Loss of Mitochondrial DNA Copy Number
Kyle Thompson,1,20 Homa Majd,2,20 Cristina Dallabona,3,20 Karit Reinson,4,5,20 Martin S. King,2
Charlotte L. Alston,1 Langping He,1 Tiziana Lodi,3 Simon A. Jones,6 Aviva Fattal-Valevski,7
Nitay D. Fraenkel,8 Ann Saada,9 Alon Haham,10 Pirjo Isohanni,11,12 Roshni Vara,13 Ineˆs A. Barbosa,14
Michael A. Simpson,14 Charu Deshpande,15 Sanna Puusepp,4,5 Penelope E. Bonnen,16
Richard J. Rodenburg,17 Anu Suomalainen,11,18 Katrin O˜unap,4,5 Orly Elpeleg,19 Ileana Ferrero,3
Robert McFarland,1 Edmund R.S. Kunji,2,21 and Robert W. Taylor1,21,*
Mutations in SLC25A4 encoding the mitochondrial ADP/ATP carrier AAC1 are well-recognized causes of mitochondrial disease. Several
heterozygous SLC25A4mutations cause adult-onset autosomal-dominant progressive external ophthalmoplegia associated with multi-
ple mitochondrial DNA deletions, whereas recessive SLC25A4 mutations cause childhood-onset mitochondrial myopathy and cardio-
myopathy. Here, we describe the identification by whole-exome sequencing of seven probands harboring dominant, de novo
SLC25A4mutations. All affected individuals presented at birth, were ventilator dependent and, where tested, revealed severe combined
mitochondrial respiratory chain deficiencies associated with a marked loss of mitochondrial DNA copy number in skeletal muscle. Strik-
ingly, an identical c.239G>A (p.Arg80His) mutation was present in four of the seven subjects, and the other three case subjects harbored
the same c.703C>G (p.Arg235Gly) mutation. Analysis of skeletal muscle revealed a marked decrease of AAC1 protein levels and loss of
respiratory chain complexes containingmitochondrial DNA-encoded subunits. We show that both recombinant AAC1mutant proteins
are severely impaired in ADP/ATP transport, affecting most likely the substrate binding and mechanics of the carrier, respectively. This
highly reduced capacity for transport probably affects mitochondrial DNAmaintenance and in turn respiration, causing a severe energy
crisis. The confirmation of the pathogenicity of these de novo SLC25A4 mutations highlights a third distinct clinical phenotype asso-
ciated with mutation of this gene and demonstrates that early-onset mitochondrial disease can be caused by recurrent de novo muta-
tions, which has significant implications for the application and analysis of whole-exome sequencing data in mitochondrial disease.Introduction
Mitochondria are essential organelles involved in a wide
range of cellular processes, including iron-sulfur cluster
formation, amino acid and fatty acid synthesis anddegrada-
tion, the tricarboxylic acid cycle, heme synthesis,
and production of ATP via oxidative phosphorylation
(OXPHOS). Mitochondria contain their own genome
(mtDNA) that encodes 2 rRNAs, 22 tRNAs, and 13 polypep-
tides,1 all of which are hydrophobic subunits of the
complexes involved in OXPHOS. The maintenance and
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genome. Mitochondrial disease results from a disruption
of this complex bi-genomic control of OXPHOS and may
arise from a wide range of genetic defects, which, in turn,
result in a vast array of clinical features. In these circum-
stances, achieving a genetic diagnosis can be challenging.
However, the advent of next-generation sequencing
has greatly improved the prospect of achieving a genetic
diagnosis for affected individuals and the spectrum ofmito-
chondrial disease-causingmutations continues to expand.2
Whole-exome sequencing (WES) has identified many of
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in addition to the proband is an efficient means of deter-
mining segregation of suspected pathogenic variants.
Mitochondrial carriers represent a large group of nu-
clear-encoded mitochondrial proteins with diverse sub-
strates. The transport steps performed by these carriers
are required for the processes in mitochondria described
above and for the replication, transcription, and transla-
tion of mtDNA.4 They typically consist of three homolo-
gous sequence repeats5 and cycle between two states: the
cytoplasmic state in which the substrate-binding site is
open to the intermembrane space and the matrix state in
which the substrate-binding site is open to the mitochon-
drial matrix. An increasing number of mutations in genes
encoding mitochondrial carriers have been reported to
cause mitochondrial disease.6
One of these, the mitochondrial ADP/ATP carrier (AAC)
imports ADP into themitochondrion and exports ATP into
the intermembrane space, which is confluent with the
cytosol.7 Given its pivotal role, it is not surprising that
mutations in the ADP/ATP carrier are associated withmito-
chondrial disease.8–16 The ADP/ATP carrier has four tissue-
specific isoforms in humans, which are encoded by four
closely related nuclear genes.17 The isoform expressed at
high levels in skeletal muscle, heart, and brain is AAC1
(also known as ANT1) and is encoded by SLC25A4 (MIM:
103220) located on the sub-telomeric region of chromo-
some 4q.18,19
Several mutations in SLC25A4 have been linked to mito-
chondrial disorders and fall into two distinct clinical phe-
notypes: null recessive mutations causing a mitochondrial
myopathy and cardiomyopathy phenotype that presents
in childhood or early adulthood and is characterized
by fatigue and exercise intolerance (also described as
mitochondrial DNA depletion syndrome type 12 [MIM:
615418])13–16 and several single heterozygous mutations
reported in cases of adult-onset autosomal-dominant
progressive external ophthalmoplegia (adPEO [MIM:
609283]).8–12 Here we present the clinical, biochemical,
and functional characterization of previously undocu-
mented, recurrent, de novo dominant mutations in
SLC25A4 identified by WES in seven affected individuals
with a characteristic and severe early-onset mitochondrial
disease presentation representing a third distinct pheno-
typic group associated with SLC25A4 mutations.Material and Methods
Muscle Histology and Biochemistry
Informed consent with appropriate ethics review committee
approvals were obtained for all families. Histological and histo-
chemical analyses were performed on 10 mm transversely orien-
tated serial cryosections of skeletal muscle biopsy samples using
standard procedures where available. The activities of individual
respiratory chain complex activities and citrate synthase, a mito-
chondrial matrix marker, were determined in muscle homoge-
nates for subjects 1, 2, and 5 as previously described.20 Complex
I, complex IIþIII, and complex IV activities were measured in sub-The Americject 3 as previously described.21 The respiratory chain enzyme ac-
tivities CI þ III, CII þ III, CII, CIV, and citrate synthase were
analyzed in subject 6 as previously described.22Whole-Exome Sequencing
All subjects underwent routine mtDNA diagnostic testing
including assessment of mtDNA copy number by qPCR and
sequencing of the mitochondrial genome. Whole-exome cap-
ture, sequencing, and variant filtering/prioritization was per-
formed for subject 1, as previously described.3 WES was
performed in the family trio of subject 2 using Agilent
SureSelectXT All Exon v.5 according to manufacturer’s instruc-
tions followed by sequencing on an Illumina HiSeq2500 plat-
form with 100 bp paired-end reads. Variant calls were generated
with an in-house pipeline as previously described23 with minor
alterations. In brief, resulting reads were aligned to the reference
genome (hg19) with the Novoalign (Novocraft Technologies Sdn
Bhd) alignment tool. Clonal reads resulting from polymerase
chain reaction, optical errors, and reads mapping to multiple lo-
cations were discarded from further analyses. SNPs and small
insertion deletions were identified and filtered for quality with
SAMtools. Variant files were annotated with respect to genes
and variant functional consequences using ANNOVAR tool.
Further annotation included information on variant novelty
and estimated population frequencies by cross-referencing iden-
tified variants with publically available data (dbSNP135, 1000
Genomes database) and >1,000 control exomes processed with
the pipeline described above.
WES of subject 3 was performed as described previously.24,25
Variants in genes with (predicted) mitochondrial function were
filtered based on frequency in publically available databases
(dbSNP, ExAC) and an in-house database, revealing the likely
pathogenic heterozygous variant in SLC25A4. Identification of
mitochondrial disease-causing variants was achieved by filtering
data using publically available databases of genes with known
or predicted mitochondrial function and of genes previously asso-
ciated with related clinical phenotypes. Rare (minor allele fre-
quency < 0.01) and previously unobserved alleles under both
dominant and recessive models in each affected individual were
evaluated.
For subjects 4 and 5, WES was performed as previously
described.26 For subject 6, WES was undertaken as described27,28
using ANNOVAR and SAMtools. Publically available databases
(1000 Genomes, ExAC, MitoCarta) and data from the Sequencing
Initiative Suomi Project (SISu), an exome data collection of more
than 6,000 Finnish individuals, were used for further variant
filtering alongside in-house exome repositories.Construction of Lactococcal Expression Strains and
Site-Directed Mutagenesis
Codon-optimized SLC25A4 was synthesized by GenScript. Site-
directed mutations were introduced by overlap-extension PCR29
with KOD HotStart polymerase (Novagen). Wild-type and mutant
genes were cloned into the expression vector pNZ8048 under the
control of a nisin A-inducible promoter.30,31 The plasmid was
transformed in L. lactis strain NZ9000 by electroporation, as previ-
ously described.31 Vectors were isolated by miniprep (QIAGEN),
according to the manufacturer’s instructions with one alteration;
10 mg/mL lysozyme was added to the lysis buffer and the resus-
pended cells were incubated at 55C for 20 min prior to lysis;
Sanger sequencing confirmed successful transformants.an Journal of Human Genetics 99, 860–876, October 6, 2016 861
Growth of Lactococcus lactis and Membrane Isolation
Pre-cultures of L. lactiswere obtained by inoculating M17medium
supplemented with 1% (w/v) glucose and 5 mg/mL chloramphen-
icol from glycerol stocks and incubating the cultures overnight at
30C with no aeration. The OD600 was measured and the cells
diluted to a starting OD600 of 0.1 in fresh M17 medium supple-
mented with 1% (w/v) glucose and 5 mg/mL chloramphenicol.
Cells were grown at 30Cwith no aeration until the OD600 reached
0.5; the expression of the recombinant proteins was induced by
addition of nisin A with a dilution of 1:10,000 of spent M17 me-
dium from nisin A excreting L. lactis strain NZ9700. The cells
were grown for a further 140min at 30C, harvested by centrifuga-
tion (6,0003 g, 15 min, 4C), resuspended in PIPES buffer (10 mM
PIPES [pH 7.0], 50 mM NaCl), and collected by centrifugation.Sample Preparation, SDS-PAGE, and Western Blot
Analysis
Human fibroblasts were trypsinized, pelleted, and resuspended in
cell lysis buffer (50 mM Tris-HCl [pH 7.5], 130 mM NaCl, 2 mM
MgCl2, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride
[PMSF], and protease inhibitor cocktail [Pierce]). Cell lysates were
vortexed briefly and centrifuged at 500 3 g for 5 min at 4C
and the supernatant was retained. Skeletal muscle samples were
powdered in liquid nitrogen using pestle and mortar. 1 mL of
RIPA buffer (1% Igepal, 1.5% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulfate [SDS], 10 mM b-mercaptoe-
thanol, 1 mM PMSF, and 13 EDTA free protease inhibitor cocktail
[Pierce]) was added to powdered tissue and incubated on ice for
45 min. After 2 3 15 s homogenization with a polytron homoge-
nizer, muscle lysates were cleared by centrifugation at 14,000 3 g
for 10 min at 4C and supernatant retained. Cell and muscle ly-
sates were incubated with sample dissociation buffer (final con-
centrations: 6.25 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol,
0.01% bromophenol blue, and 100 mM DTT) for 30 min at
37C, separated by 12% SDS-PAGE and immobilized by wet trans-
fer (100 V, 1 hr at 4C) on to PVDFmembrane (Immobilon-P, Milli-
pore) in 25 mM Tris, 192 mM glycine, 0.02% SDS, and 15%meth-
anol. Proteins of interest were bound by overnight incubation at
4C with antibodies against COXI (Abcam cat# ab14705, RRID:
AB_2084810), SDHA (Abcam cat# ab14715, RRID: AB_301433),
Porin/VDAC1 (Abcam cat# ab14734, RRID: AB_443084), UQCRC2
(Abcam cat# ab14745, RRID: AB_2213640), NDUFB8 (Abcam
cat# ab110242, RRID: AB_10859122), ATP5A (Abcam cat#
ab14748, RRID: AB_301447), OXA1L (Proteintech cat# 21055-1-
AP, RRID: AB_10695769), ANT1 (Abcam cat# ab110322, RRID:
AB_10862212), and TIMM22 (Abcam cat# ab167423) followed
by HRP-conjugated secondary antibodies (Dako Cytomation)
and visualized using ECL-prime (GE Healthcare) and BioRad
ChemiDoc MP with Image Lab software.
For analysis of membrane fractions from L. lactis, membrane
proteins were separated by SDS-PAGE and stained by Instant
Blue. For western blotting, proteins were transferred to PVDF
membranes and probed with an anti-AAC antibody produced
in chicken at 1:20,000 dilution for 1 hr, followed by an anti-
chicken-HRP conjugate at 1:20,000 dilution for a further hour.
The membrane was developed using Amersham ECL western
blotting detection system for 30 min.Transport Assays
Transport assays were carried out using a Hamilton MicroLab Star
robot (Hamilton Robotics Ltd). Transport of 14C-labeled ADP (Per-862 The American Journal of Human Genetics 99, 860–876, Octoberkin Elmer) was initiated by the addition of 100 mL PIPES buffer
with 1.5 mM 14C-ADP to approximately 200 mg whole cells in a
MultiScreenHTS-HA 96-well filter plate (pore size ¼ 1 mm; Milli-
pore). The transport was stopped at 0 s, 20 s, 40 s, 60 s, 90 s,
120 s, 300 s, 600 s, 900 s, 10 min, 20 min, and 30 min by the addi-
tion of 200 mL ice-cold PIPES buffer and rapid filtration, followed
by two additional wash steps with 200 mL ice-cold PIPES buffer.
Levels of radioactivity in the vesicles were measured by adding
200 mL MicroScint-20 (Perkin Elmer) and by quantifying the
amount of radioactivity with the TopCount scintillation counter
(Perkin Elmer). Initial rates were determined by linear regression.Yeast Strains, Plasmids, and Media
Yeast strains used were W303-1B (MATa ade2-1 leu2-3,112 ura3-1
his3-22,15 trp1-1 can1-100 AAC1 AAC2)32 and its isogenic aac1
aac2 mutant WB12 (MATa ade2-1 trp1-1, ura3-1 can1-100 aac1::
LEU2 aac2:: HIS3).33
Strains were grown in SC synthetic defined media (0.19% YNB
without amino acids and NH4SO4 powder (Formedium), 0.5%
NH4SO4) supplemented with 1 gr/L dropout mix without ura-
cil.34 Media were supplemented with various carbon sources at
2% (w/v) (Carlo Erba Reagents), in liquid phase or after solidifica-
tion with 20 g/L agar (Formedium).
The aac2Arg96His and aac2Arg252Gly mutant alleles were obtained
by PCR overlap technique with appropriate primers (details
available on request) using the pFL38-AAC2 as template.35 The ob-
tained fragment was cloned into the SalI-BamHI-digested pFL38.36
WB12 or W303-1B were transformed with pFL38-AAC2, pFL38-
aac2Arg96His, pFL38-aac2Arg252Gly, or the empty vector pFL38
through the Li-Ac method.37Growth of S. cerevisiae, Membrane Isolation, and
Fusions
Pre-cultures of S. cerevisiae were obtained by inoculating SC
without uracil þ 2% glucose medium from glycerol stocks
and incubating the cultures overnight at 30C with shaking at
225 rpm. The OD600 was measured and the cells diluted to a start-
ing OD600 of 0.1 in fresh SC without uracil þ 2% glucose medium.
Cells were grown at 30C with shaking at 225 rpm for 20 hr. Cells
were harvested by centrifugation (6,0003 g, 15 min, 4C), washed
in ice-cold MilliQ, and centrifuged as before. The cells were resus-
pended in breaking buffer (650 mM sorbitol, 100 mM Tris-HCl
[pH 8.0], 5 mM EDTA, 5 mM amino hexanoic acid, 5 mM benza-
midine, 0.2% BSA) and disrupted mechanically with a cell disrup-
tor (Constant Systems) at 33,000 psi. Whole cells and debris were
removed by centrifugation (10,800 3 g, 15 min, 4C), and the
membranes were collected by ultracentrifugation (138,000 3 g,
1 hr, 4C). Pellets were resuspended in washing buffer (650 mM
sorbitol, 100 mM Tris-HCl [pH 8.0], 5 mM amino hexanoic acid,
5 mM benzamidine) and collected by ultracentrifugation as
before. Pellets were finally resuspended in PIPES buffer (10 mM
PIPES [pH 7.0], 50 mM NaCl) to a total protein concentration of
approximately 3 mg/mL and stored in liquid nitrogen.
To make membrane fusions, 1 mg yeast membranes were mixed
with 5 mg 3:1 E. coli polar lipid extract and egg yolk phosphatidyl-
choline (Avanti Polar Lipids) liposomes, diluted to a final volume
of 900 mL with PIPES, and fused by seven cycles of freezing in
liquid nitrogen and thawing at room temperature before storage
in liquid nitrogen. The membrane vesicle fusions were thawed
and 100 mL 50 mM ADP added. Vesicles were extruded 11
times through a 1 mm pore size polycarbonate filter, passed6, 2016
through a pre-equilibrated PD10 column to remove external sub-
strate, collected in 1.6 mL PIPES buffer, and diluted 4-fold before
use. Transport experiments were carried out as described above.
Drop Tests
Pre-cultures of S. cerevisiae were obtained by inoculating SC
without uracil þ 2% glucose medium from glycerol stocks and
incubating the cultures overnight at 28C with shaking at
225 rpm. Cells were collected by centrifugation (3,000 rpm,
2 min, room temperature), washed twice with MilliQ, and diluted
to a starting OD600 of 1.0. A serial 10-fold dilution was set up in
sterile MilliQ, and 5 mL of each dilution was dispensed onto SC
plates without uracil, supplemented with either 2% glucose, 2%
ethanol, or 2% glycerol. The plates were incubated at 28C or
37C for 72 hr.
Yeast Analysis
Respiratory activity was performed as previously described.38,39
Reduced versus oxidized cytochrome spectra of yeast cells cultured
for 24 hr at 37C in SC without uracil, supplemented with glucose
at non-repressing concentration of 0.6% were recorded (Varian
Cary300 UV-VIS Spectrophotometer) at room temperature.Results
Case Reports
Subject 1
This female infant was born at full term via Caesarean sec-
tion for abreechpresentation tonon-consanguineouswhite
Britishparentswithahealthyolder sister. Sherequiredventi-
lation at birth and was noted to have elevated lactate levels
in blood shortly after birth, requiring correction with so-
dium bicarbonate. Plasma lactate levels ranged from 3 to
15 mmol/L (normal range, 0.7–2.1 mmol/L), and her CSF
lactate was also elevated. Echocardiography showed mild
left ventricular hypertrophy and urine organic acid testing
detected low levels of ethylmalonic acid. Although she was
profoundly hypotonic, her cranial MRI was reported as
normal for age. Despite multiple attempts to extubate she
did not demonstrate any improvement in respiratory drive
and after obtaining a diagnostic muscle biopsy, care was
withdrawn at 14 days. The parents have since had a healthy
son (Figure 1).
Subject 2
This male infant was born to non-consanguineous white
British parents after an unremarkable pregnancy. Labor
was induced at 42 weeks and he was delivered by ventouse
extraction weighing 4,260 g. Apgar scores were 10 and 10
at 1 and 5 min, respectively, but he developed tachypnoea
and signs of respiratory distress at 10 hr, requiring intuba-
tion and mechanical ventilation. Serial blood gases re-
vealed profound and persistent lactic acidosis (peak lactate
of 14 mmol/L) with concomitant elevation of CSF lactate
(3.3mmol/L). Blood cultures identified Enterococcus faecalis
and he received treatment with intravenous antibiotics.
Echocardiogram and electroencephalogram were normal,
but cranial MRI scan showed a small infarct in the right
thalamus. Skeletal muscle biopsy revealed evidence ofThe Americmitochondrial disease (Table 1). There was no improve-
ment in the lactic acidosis despite antibiotic, biotin, thia-
mine, and ubiquinone treatment. Attempts to extubate
were unsuccessful on several occasions and the family
agreed to a palliative care approach. Discharge to a hospice
for terminal care took place 9 days after birth.
Subject 3
This female infant was born at term weighing 3,520 g and
was the second child of healthy non-consanguineous Esto-
nian parents. She was floppy at birth with paucity of limb
movements and hyporeflexia. She required low-level sup-
plemental oxygen in the immediate postnatal period, but
was breathing air from 5 to 48 hr of age, at which point
she deteriorated with a decrease in conscious level, feeding
difficulties, and respiratory impairment. She was intubated
and mechanically ventilated. Elevated lactate was noted in
blood (9.7 mmol/L, normal < 2.2 mmol/L) and cerebrospi-
nal fluid (4.8 mmol/L, normal range 1.1–2.4 mmol/L).
Urine analysis revealed increased excretion of lactate, 2-hy-
droxybutyric acid, fumarate, ketoglutarate, ethylmalonate,
and 4-hydroxyphenyl lactate. Echocardiography showed a
mildly enlarged apex of the left ventricle. At day 7, despite
treatment with coenzyme Q10 (20 mg/kg/day), riboflavin
(100 mg/kg/day), creatine (200 mg/kg/day), and L-carni-
tine (100mg/kg/day), she developed persistent generalized
clonic seizures without electroencephalographic (EEG)
abnormalities. Serial MRIs initially demonstrated commu-
nicating hydrocephalus and subsequently progressive ce-
rebral white matter atrophy. Presently, at 6 years, she has
a tracheostomy, is unable to speak, and can breathe inde-
pendently for less than 1 hr. She is reliant on a wheelchair
due to proximal muscle weakness, but can walk briefly
with a frame. Communication is by pointing or pictogram.
Subject 4
This female was born to Ashkenazi Jewish parents after an
IVF pregnancy that was remarkable for intrauterine growth
retardation, cardiac echogenic focus, and enlarged renal
pelvis on fetal ultrasound. She was delivered at 28 weeks
gestation by emergency cesarean section due to maternal
HELLP (hemolysis, elevated liver enzymes, and low plate-
lets) syndrome, weighed 920 g, and had Apgar scores of 5
and 8 at 1 and 5 min, respectively. She required intubation
and ventilation for respiratory distress syndrome and
required dopamine for hypotension. A patent ductus arte-
riosis (PDA) was treated with ibuprofen. Brain ultrasound
revealed a small asymmetric, predominantly left-sided,
grade II intraventricular hemorrhage, though subsequent
cranial MRI was normal. Bronchoscopy and chest CT
were normal but she became ventilator dependent. Car-
diac echo revealed hypertrophic cardiomyopathy that
was resolved after steroid therapy was stopped. Tracheos-
tomy was performed at 5 months and a gastrostomy with
fundoplication at 6 months. At the age of 7 months she
was hypomimic, dysphagic, and profoundly hypotonic.
She had tongue fasciculation, was areflexic, and had
no antigravity limb movements, but electromyography
showed no evidence of myopathy or denervation, thoughan Journal of Human Genetics 99, 860–876, October 6, 2016 863
Figure 1. The c.239G>A (p.Arg80His) and c.703C>G (p.Arg235Gly) SLC25A4 Mutations Are De Novo Affecting Evolutionary
Conserved Residues
(A) Pedigrees of six families showing each clinically affected subject and confirmatory sequencing chromatograms to show that the
c.239G>A (p.Arg80His) or c.703C>G (p.Arg235Gly) heterozygous variants in each affected individual are not present in respective
parental samples, indicating de novo occurrence.
(B) Multiple sequence alignment of this region of the AAC1 amino acid sequence (GenBank: NP_001142.2) was performed using
ClustalOmega and confirms that the p.Arg80His (left) and p.Arg235Gly (right) alterations affect evolutionarily conserved residues
(shaded blue).single-fiber results suggested a possible congenital myas-
thenia. Treatment with mestinone, ephedrine, and albute-
rol did not improve her condition. Urinary Krebs cycle
metabolites included fumarate, alpha-ketoglutarate, and
succinate. Marked dicarboxylic acids were also identified,
with increased glutaric acid, 2-hydroxyglutaric, ethylma-
lonic, andmethylsuccinic acid. The child developed atopic
dermatitis and severe allergy to sesame and peanuts. Audi-
tory brain stem response showed mild conductive hearing
impairment. Ophthalmologic examination was normal. At
present, aged 4 years, she has normal cognition and is fed
via gastrostomy, requiring ventilation 24 hr a day. She re-
mains markedly hypotonic and weak, being unable to864 The American Journal of Human Genetics 99, 860–876, Octobercrawl or stand. She has very limited verbal communication
but receptive language is good and she communicates with
a computerized aid. The parents have since had a healthy
daughter, who was naturally conceived.
Subject 5
This male infant was born to Ashkenazi Jewish parents at
39 weeks gestation after a normal pregnancy and weighed
3,250 g. He had Apgar scores of 1, 4, and 7 at 1, 5, and
10 min, respectively, and required suction of meconium
from his airways, intubation, and mechanical ventilation.
On admission to the neonatal intensive care unit, he was
noted to be profoundly hypotonic with severe head
lag and had bilateral abnormalities of his wrist joints.6, 2016
Table 1. Biochemical and Clinical Findings in Individuals with De Novo SLC25A4 Mutations
Subject
Details SLC25A4 Variant Assessment of Skeletal Muscle Clinical Features
ID Sex
cDNA (NM_001151.3),
Protein (NP_001142.2)
Muscle Biopsy
Findings RCC
% Mean Enzyme
Activity
Absolute
Values
Control Mean
(Reference Range)
mtDNA Copy
Number
Age of
Onset
Clinical
Course
Other Clinical Features
and Relevant Family History
1 female c.239G>A
(p.Arg80His)
global COX deficiency;
excessive lipid
accumulation
I 5% (YYY) 0.005 0.104 5 0.036 (n ¼ 25) <5% birth died 14 d ventilator dependent from
birth, hypotonia, raised CSF
and serum lactate,
hypertrophic cardiomyopathy
II 172% 0.25 0.145 5 0.047 (n ¼ 25)
III 16% (YY) 0.089 0.554 5 0.345 (n ¼ 25)
IV 9% (YYY) 0.098 1.124 5 0.511 (n ¼ 25)
2 male c.239G>A
(p.Arg80His)
global COX deficiency;
occasional fibers showing
enhanced mitochondrial
activity; excessive
lipid accumulation
I 17% (YY) 0.018 0.104 5 0.036 (n ¼ 25) <5% birth died 9 d ventilator dependent, raised
CSF and serum lactate,
encephalopathy, seizuresII 177% 0.256 0.145 5 0.047 (n ¼ 25)
III 20% (YY) 0.112 0.554 5 0.345 (n ¼ 25)
IV 14% (YY) 0.16 1.124 5 0.511 (n ¼ 25)
3 female c.239G>A
(p.Arg80His)
excessive lipid accumulation
on histology and EM;
mitochondria showing
disorganization of cristae
structure
I 18% (YY) 28 154 5 59 (n ¼ 8) z34% birth alive 6 y ventilator dependent, paucity
of limb movements, raised
CSF and serum lactate,
seizures, wheelchair bound,
tracheostomized
IIþIII 46% (Y) 51 110 5 70 (n ¼ 8)
IV 5% (YYY) 58 1150 5 400 (n ¼ 8)
4 female c.239G>A
(p.Arg80His)
ND I ND ND ND ND birth alive 4 y ventilator dependent from
birth, tracheostomized,
paucity of limb movementsII
III
IV
5 male c.703C>G
(p.Arg235Gly)
global COX
deficiency
I 12% (YY) 0.014 0.116 5 0.018 (n ¼ 40) 20% birth died 3 m ventilator dependent, paucity
of limb movements, lactic
acidosis, concentric
hypertrophy, tracheostomized,
died after cardiac arrest
II 116% 0.108 0.097 5 0.015 (n ¼ 40)
IIþIII 1% (YYY) 0.014 0.142 5 0.039 (n ¼ 40)
IV 5% (YYY) 0.033 0.664 5 0.113 (n ¼ 40)
6 male c.703C>G,
(p.Arg235Gly)
global COX
deficiency
IþIII 109% 153 140 5 70 (n ¼ 7) ND birth died 1.5 m identical twin brother of
subject 7, ventilator dependent
from birth, raised CSF and
serum lactate
II 57% 93 162 5 57 (n ¼ 7)
IIþIII 25% (YY) 49 197 5 88 (n ¼ 7)
IV 3% (YYY) 88 2521 5 759 (n ¼ 7)
7 male c.703C>G
(p.Arg235Gly)
ND I ND ND ND 11%–13% birth died 1.5 m identical twin brother of
subject 6, lack of respiratory
drive from birth, ventilator
dependent, raised CSF and
serum lactate
II
III
IV
Respiratory chain complex (RCC) activities are expressed as nmols of substrate.min1.unit citrate synthase1. Y, %50% control enzyme activity; YY, %25% control enzyme activity; YYY,%10% control enzyme activity.
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Respiration deteriorated, primary pulmonary hyperten-
sion of the newborn (PPHTN) was suspected, and treat-
ment with nitric oxide (up to 40 ppm) and continuous
inotropic therapy was initiated. Despite aggressive man-
agement, echocardiogram performed a few hours later
demonstrated severe PPHTN, though this did improve
over the course of the following 2 weeks. Attempted
extubation at this point was, however, unsuccessful;
he developed paradoxical breathing and bradycardia.
Neurological status deteriorated over the following week,
with increasing hypotonia, paucity of limb movement,
generalized weakness, hypomimia, tongue fasciculation,
dysphagia, and apnea. He was noted to be areflexic and a
diagnosis of spinal muscular atrophy was considered. Lab-
oratory investigations revealed elevated blood lactate
(15 mmol/L; normal range 0.9–2 mmol/L) and hyperam-
monemia (300 mcg/dL; normal < 50 mcg/dL) that subse-
quently normalized. Blood amino acids and urinary amino
and organic acids were normal. Repeat echocardiogram re-
vealed concentric hypertrophy and although cranial MRI
demonstrated a normal brain structure, there were small
subacute infarcts in the splenium of the corpus callosum
and right thalamus consistent with hypoxic ischemic en-
cephalopathy. Tracheostomy and a feeding jejunostomy
were inserted but at the age of 3 months, after a gradual
worsening in cardiac hypertrophy and cardiac function,
the child suffered a fatal cardiac arrest.
Subject 6
This identical twin brother of subject 7 was born to non-
consanguineous Finnish parents. The twin pregnancy
was normal until 33 weeks when there was a spontaneous
rupture of membranes. He was delivered by Ventouse
extraction weighing 1,855 g with Apgar scores of 8 and 7
at 1 and 5 min, respectively. He was hypotonic and had
breathing difficulties from birth that progressed quickly
to apnea and dependence on mechanical ventilation. His
respiratory drive showed no improvement and he died at
6 weeks of age. Laboratory investigations showed elevated
lactate in both blood (5.2 mmol/L; normal range 0.7–
1.8 mmol/L) and CSF (3.9 mmol/L; normal range 0.6–
2.7 mmol/L). Brain MRI, EEG, ophthalmological examina-
tion, glucose, creatine kinase, ammonia, plasma amino
acids, urine organic acids, and phytanic acid were all
normal.
Subject 7
This identical twin brother of subject 6 was born by emer-
gency Cesarean section due to asphyxia with a birth
weight of 1,850 g and Apgar scores of 1, 2, and 3 at 1, 5,
and 10 min, respectively. He had hypoxic ischemic en-
cephalopathy (HIE), was apnoeic, and needed resuscita-
tion. He was hypotonic, had prolonged hypoventilation,
and was respirator dependent with no spontaneous breath-
ing and few spontaneous movements. As with his brother,
spontaneous respiration did not improve and he died at
1.5 months of age. EEG was initially abnormal due to
HIE, but normalized within 2 weeks. Mild periventricular
hemorrhage was seen on cranial MRI. Lactate was elevated866 The American Journal of Human Genetics 99, 860–876, Octoberin blood (5.4 mmol/L; normal range 0.7–1.8 mmol/L) and
CSF (4.2 mmol/L; normal range 0.6–2.7 mmol/L) and
excretion in urine was also elevated. Cardiac and abdom-
inal ultrasound, ophthalmological examination, electro-
myography, ammonia, urine metabolic screening, and
plasma amino acids were normal.
Diagnostic Mitochondrial Investigations of Subject
Muscle
Five of the seven subjects within our cohort (subjects 1, 2,
3, 5, and 6) had diagnostic muscle biopsies for the evalua-
tion of suspected mitochondrial disease using a range of
histopathological and biochemical assays (Table 1). Cyto-
chrome c oxidase (COX) oxidative enzyme histochemistry
in muscle from subjects 1 and 2 revealed a generalized loss
of enzyme activity (Figure S1); the SDH reaction in subject
2 showed fibers with enhanced mitochondrial activity
while Oil Red O (subject 1) or Sudan Black (subject 2)
staining confirmed prominent lipid accumulation (Fig-
ure S1). Histopathological assessment of subject 3’s muscle
biopsy revealed small and rounded muscle fibers with little
variation in fiber size and without evidence of atrophy,
necrosis, fibrosis, or inflammatory changes; Oil Red O
staining showed lipid deposition (Figure S1) and modified
Gomori trichrome staining disclosed abnormal staining
around the subsarcolemmal region of some fibers; unfor-
tunately, histochemical assessment of oxidative enzyme
activities was not undertaken. Electron microscopy
investigation confirmed the accumulation of both lipid
and glycogen, revealing numerous mitochondria with
disorganized cristae (Figure S1), although paracrystalline
inclusions were not detected.
The assessment of mitochondrial respiratory chain com-
plex activities in subjects 1, 2, and 5 showed decreased
activities of complexes I, III, and IV, with a compensatory
increase in the activity of complex II (Table 1). Subject 3
showed low complex I and IV activities in muscle, while
the combinedmeasurement of complexes IIþIII (succinate:
cytochrome c reductase activity) was within the normal
range. Subject 6 also had impaired complex IV activity
and whereas the combined measurement of complexes
IIþIII were also low, the combined measurement of com-
plexes IþIII was within the normal range (Table 1). These
defects in OXPHOS enzyme activities were associated with
mtDNA depletion in subject muscle; qPCR revealed a strik-
ing loss ofmtDNA copy number to<5%of control levels in
both subjects 1 and 2, whereas subjects 3, 5, and 7 demon-
strated decreased levels between 11%–34%of control levels
(Table 1).
Molecular Genetic Investigations
The demonstration of severe mtDNA depletion prompted
screening of genes associated with mtDNA depletion
myopathy (TK2 and RRM2B) in subjects 1 and 2 prior
to WES. In subject 3, mutations in POLG and TK2 were
excluded after chromosomal microarray analysis re-
vealed no abnormalities. Subjects 6 and 7 were previously6, 2016
Figure 2. The p.Arg80His and p.Arg235Gly Alterations Cause Decreased AAC1 Levels and Loss of OXPHOS Subunits Specifically in
Skeletal Muscle
(A) Western blot analysis of OXPHOS complex subunits and AAC (Abcam cat# ab110322, RRID: AB_10862212) performed on skeletal
muscle lysates from subject 1 (p.Arg80His).
(B) Western blot analysis of OXPHOS complex subunits and AAC (all isoforms) performed on skeletal muscle samples from subject 5
(p.Arg235Gly).
(C) Western blot analysis of OXPHOS complex subunits performed on fibroblast lysates from subject 1.screened for mutations in mtDNA, SCO2, TK2, and
DGUOK.
WES data from subject 1 was reported in a large study of
individuals with multiple mitochondrial respiratory chain
deficiencies (patient number 43),3 identifying several un-
documented heterozygous variants in mitochondrially tar-
geted candidates. Subsequent Sanger sequencingof parental
samples revealed that the heterozygous c.239G>A
(p.Arg80His) SLC25A4 (GenBank: NM_001151.3; ClinVar:
SCV000297809) variant was de novo, later confirmed by
microsatellite analysis to firmly establish the parentage
of subject 1 (data not shown). WES of subjects 2, 3,
and 4—undertaken at different mitochondrial diagnostic
centers—identified the identical heterozygous c.239G>A
(p.Arg80His) SLC25A4 mutation. Given the similarity in
clinical presentation, it was deemed highly likely that
this de novo variant was pathogenic; indeed, for subject 2,
WES was undertaken for the family trio, with the
absence of themutation in all parental samples designating
a de novo origin. Sanger sequencing of parental samples
firmly established that the c.293G>A mutation had
arisen independently in each of the four case subjects
(Figure 1A).
WES of subject 5 identified a different heterozygous
SLC25A4 mutation, c.703C>G (p.Arg235Gly). The simi-
larity in clinical features between subject 5 and subjects
1–4 suggested that this missense mutation was likely dis-
ease causing. Subsequently, we became aware of twins
(subjects 6 and 7) that had a very similar clinical course
to the other affected individuals and had remainedwithout
a genetic diagnosis after WES. Revisiting these data
facilitated the identification of an identical c.703C>G
(p.Arg235Gly) SLC25A4 mutation in both individuals,
which had previously not been considered during variant
filtering based on a presumed autosomal-recessive cause
of their disease phenotype. Sanger sequencing confirmed
the presence and de novo nature of the c.703C>G
(p.Arg235Gly) mutation in subject 5. In the case of subjectsThe Americ6 and 7, Sanger sequencing confirmed the presence of the
c.703C>G (p.Arg235Gly) mutation in each affected indi-
vidual and the absence of the mutation in the mother,
but unfortunately the father’s DNA sample was not avail-
able for genetic analysis.
The de novo c.239G>A (p.Arg80His) mutation is
predicted to be pathogenic based on various in silico
prediction tools including PolyPhen-2 (HumDiv score
0.966),40 SIFT (score 0),41 and CADD (phred score 34).42
The amino acid position is highly conserved across
different species (Figure 1B) (PhyloP score 6.072). The
c.703C>G (p.Arg235Gly) mutation is also predicted to
be pathogenic based on PolyPhen-2 (HumDiv score
0.883),40 SIFT (score 0),41 and align GVGD (Class C65,
GV: 0.00, GD: 125.13)43 and the amino acid is notably
conserved throughout evolution (Figure 1B).
Steady-State Levels of Respiratory Chain Components
and AAC1 Protein
Western blot analysis of muscle lysate from subject 1
(p.Arg80His) showed a decrease in the steady-state levels
of OXPHOS components of complex I (NDUFB8), complex
III (UQCRC2), and complex IV (COXI) with an increase
in SDHA (complex II) expression (Figure 2A). A similar
OXPHOS defect was seen in skeletal muscle from subject
5 (p.Arg235Gly) (Figure 2B). These data corroborate the
pattern of respiratory chain complex deficiencies observed
by direct enzyme assay (Table 1). Furthermore, skeletal
muscle from each affected individual clearly showed
decreased steady-state levels of AAC1, confirming a func-
tional consequence of both de novo SLC25A4 mutations
(Figures 2A and 2B). The expression of ADP/ATP carrier
isoforms differs between tissues. Skin cells predominantly
express AAC2 (also known as ANT2, encoded by
SLC25A5 [MIM: 300150]) and very little AAC1.19 Conse-
quently, subject fibroblasts did not express the OXPHOS
defect observed in muscle as analyzed by western blot
(Figure 2C).an Journal of Human Genetics 99, 860–876, October 6, 2016 867
Figure 3. The Functional Elements of the Human Mitochondrial ADP/ATP Carrier
(A) Transport cycle of the ADP/ATP carrier. Disruption and formation of the cytoplasmic and matrix salt bridge networks (top and bot-
tom, respectively) change the accessibility of the central substrate binding site (hexagon) to either side of the membrane.44,47
(B) Lateral view of the human ADP/ATP carrier from the membrane, showing the residues of the matrix and cytoplasmic networks (blue
and red sticks) and substrate binding site (green sticks, hexagon). ADP (light blue ball and stick) and the glutamine brace (light green
stick)48 are also shown. The residues that are mutated are shown in yellow.
(C) Cytoplasmic view of the carrier showing only the residues of the proposed substrate-binding site. The residues of the p.Arg80His
(R80H) mutation are shown in yellow andmagenta, respectively. The contact points of the substrate binding site are indicated by roman
numerals.50
(D) Cytoplasmic view of the carrier showing only the residues of thematrix salt bridge network. The residues of the p.Arg235Gly (R235G)
mutation are shown in yellow andmagenta, respectively. The comparativemodel of humanAAC1 is based on the structure of the bovine
carrier46 and was extended at the C terminus. The ionic interactions are indicated with plus and minus signs.Location of the Mutations in the Mitochondrial ADP/
ATP Carrier
In the transport cycle, the mitochondrial ADP/ATP carrier
cycles between two states: a matrix state in which the cen-
tral substrate binding is accessible to the mitochondrial
matrix and a cytoplasmic state in which the binding
site is accessible to the intermembrane space, which is
confluent with the cytosol7,44 (Figure 3A). A three-fold
salt bridge network on the matrix side45,46 and on the
cytoplasmic side of the carrier44,47,48 are involved in open-
ing and closing of the carrier to either side of the mem-
brane in an alternating way, regulating access to the
central substrate binding site (Figure 3A).44 The human
carrier is closely related to the bovine carrier, for which
an atomic structure is available.46 A comparative model
of the human carrier was built to locate the position of
the p.Arg80His and p.Arg235Gly alterations. The view
from the membrane shows the location of the central sub-
strate-binding site and the matrix and cytoplasmic salt868 The American Journal of Human Genetics 99, 860–876, Octoberbridge networks (Figure 3B). The main contact points
involved in substrate binding, indicated by roman nu-
merals I, II, and III, are located on the even-numbered a
helices.49,50 The proposed substrate binding site of the hu-
man mitochondrial ADP/ATP carrier consists of Gly183,
Ile184, and Tyr187 (contact point II) for binding of the
adenine moiety and Arg80 (contact point I), Lys23, and
Arg280 (contact point III) for binding of the phosphate
groups (Figure 3C).49,50 The p.Arg80His alteration affects
contact point I of the proposed substrate-binding site
of AAC1 (Figure 3C). The histidine substitution may
conserve the positive charge, depending on the local pH
(pKa 6.0), but would introduce a shorter and less flexible
residue.
The matrix network has salt bridge interactions between
residues Lys33 and Asp232, Arg235 and Asp135, and
Arg138 and Glu30 (Figure 3D).46 In addition, there is
a glutamine brace interacting with Asp232-Lys33 resi-
dues.48 The p.Arg235Gly alteration abolishes one of the6, 2016
Figure 4. The p.Arg80His and p.Arg235Gly Alterations Impair ADP/ATP Transport
(A) ADP uptake curves of whole cells of L. lactis-expressing AAC1 (open circle), AAC1 p.Arg80His (open square), and AAC1 p.Arg235Gly
(open triangle). To determine the non-specific binding, the specific inhibitor carboxyatractyloside was added (closed symbols). The error
bars represent the standard deviation of eight assays.
(B) Residual transport activity relative to wild-type AAC1, corrected for background binding and differences in expression levels,
as determined by the uptake rate of radiolabeled ADP into L. lactis-expressing human AAC1 with de novo mutations described here
(black bars), adPEO mutations (white bars), or the recessive mitochondrial myopathy and cardiomyopathy mutations (gray bars).
The data are represented by the average and standard deviation of eight transport assays.three salt bridge interactions, which may affect the overall
strength of the matrix network and function of the
carrier.51
The p.Arg80His and p.Arg235Gly Alterations Impair
the Function of the ADP/ATP Carrier
It has been shown that human AAC1 can be expressed in
a functional form in the cytoplasmic membrane of the
Gram-positive bacterium Lactococcus lactis.52 To study
the effect of the mutations on transport activity, the
c.239G>A and c.703C>G mutations were introduced by
site-directed mutagenesis into human SLC25A4 in the
expression vector pNZ8048. The transport activity of
the carriers was determined in whole cells by monitoring
the uptake of radiolabeled ADP in exchange for endoge-
nous adenine nucleotides. To determine the non-specific
background, the specific inhibitor carboxyatractyloside
(CATR) was used in control experiments (Figure 4A). TheThe Americuptake of ADP was severely reduced in the AAC1 that con-
tained the disease mutations. Subsequently, mutants with
the previously reported SLC25A4 pathogenic mutations
were made for direct comparison. All proteins expressed
to approximately the same levels in the cytoplasmic mem-
brane of L. lactis, as judged by western blotting (Figure S2).
Initial uptake rates were determined and they were cor-
rected for differences in expression levels (Figure S2) and
for non-specific binding, using the CATR controls. For
each mutant, the residual transport rate was calculated
as a percentage of the wild-type AAC1 rate. Both the
p.Arg80His and p.Arg235Gly alterations had severe effects
on transport activity with residual transport rates of 24%
and 3%, respectively (Figure 4B). The adPEO-linked muta-
tions were generally milder with residual transport rates
ranging from 24% to 56%, whereas mutations that are re-
ported to cause autosomal-recessive disease inactivated
transport fully (<1%) (Figure 4B).an Journal of Human Genetics 99, 860–876, October 6, 2016 869
Figure 5. Phenotypic Analysis of the WB12 Strain Transformed with the Empty Vector, Wild-Type AAC2, aac2Arg96His, or aac2Arg252Gly
Mutant Allele
(A) Assessment of an oxidative growth phenotype. Equal amounts of serial dilutions of cells from exponentially grown cultures (105, 104,
103, and 102 cells) were spotted onto SC plates without uracil, supplemented with either 2% glucose, 2% ethanol, or 2% glycerol. The
growth was scored after 3 days of incubation at 28C.
(B) Cytochrome profiles of cells grown in SCwithout uracil supplemented with 0.6% glucose at 37C. The peaks at 550, 560, and 602 nm
(vertical bars) correspond to cytochromes c, b, and aa3, respectively. All the experiments were performed in triplicate.
(C) Respiratory activity (normalized to wild-type, performed in triplicate, error bars show standard deviation) and corresponding western
blot analysis to show Aac2 expression.
(D) Transport activity as determined by the uptake rate of [14C]-labeled ADP measured with fused mitochondrial membranes isolated
from yeast strains and corresponding western blot analysis to illustrate appropriate Aac2 expression. Error bars describe the standard
deviations of four assays.Complementation and Transport Studies in Yeast
Saccharomyces cerevisiae
To validate the pathogenic role of the AAC1 missense
mutations in vivo, we established ad hoc recombinant
systems in the budding yeast Saccharomyces cerevisiae,
a facultative aerobic organism. AAC2 in yeast encodes
Aac2, which is the ortholog of human mitochon-
drial AAC1. Both Arg80 and Arg235 residues of human
AAC1 are conserved, corresponding to Arg96 and
Arg252, respectively, in yeast Aac2. We introduced the
p.Arg96His and p.Arg252Gly amino acid substitutions in
the yeast Aac2 protein by site-directed mutagenesis of a re-
combinant AAC2 cloned in the centromeric pFL38 vector.
Mutant proteins were expressed in the S. cerevisiae WB12
strain (aac2) for complementation studies, as this strain
lacks functional ADP/ATP carriers, and in W303-1B
strain (AAC2), which expresses one copy of AAC2 on the
genome, to evaluate the dominance/recessivity of the
aac2Arg96His and aac2Arg252Gly mutations. The yeast strain
W303-1B AAC2 was transformed with a plasmid carrying
either wild-type AAC2 or the aac2Arg96His or aac2Arg252Gly
mutant alleles. The resulting AAC2/AAC2 homoallelic
and AAC2/aac2Arg96His or AAC2/aac2Arg252Gly heteroallelic870 The American Journal of Human Genetics 99, 860–876, Octoberstrains model the diploid genetic organization of human
cells.
Growth of yeast on either ethanol or glycerol as non-
fermentable carbon sources is critically dependent on a
functional ADP/ATP carrier and electron transport chain.
Thus, yeast transformants were analyzed first for growth
on plates containing non-fermentable carbon sources or
glucose as a control. Plates were incubated at two different
temperatures: 28C, which is the optimal temperature for
yeast, and 37C, under temperature-induced stress condi-
tions. Neither the aac2Arg96His nor aac2Arg252Gly mutant
strains were able to grow on ethanol or glycerol at either
temperature (Figure 5A), indicating that the mutant alleles
are not able to complement the OXPHOS defect of the
aac2-null mutant. The levels of expressed Arg96Hismutant
Aac2 were similar to wild-type (Figure 5C), so these data
suggest that in the aac2Arg96His strain, the transport rate
of the mutant carrier is insufficient in vivo to sustain
growth. In contrast, the p.Arg252Gly mutant Aac2 protein
was expressed at very low levels in the aac2Arg252Gly strain
(Figure 5C), which may also account for the lack of growth
on glycerol. All strains with theW303-1B background grew
on glycerol, showing that the activity of Aac2 expressed6, 2016
Figure 6. De Novo SLC25A4 Mutations
Do Not Decrease Mitochondrial Protein
Import
(A) Western blot analysis of inner mito-
chondrial membrane proteins performed
on skeletal muscle lysates from subject 2
(p.Arg80His).
(B) Western blot analysis of inner mito-
chondrial membrane proteins performed
on skeletal muscle samples from subject 5
(p.Arg235Gly).from the genome was sufficient to sustain growth and sug-
gesting that there was no dominant effect of the mutant
proteins over the wild-type proteins at the transport level.
Additional investigations were undertaken to charac-
terize the effect of the two mutations. Mitochondrial cyto-
chrome content—an index of the structural integrity of
the respiratory-chain complexes—was determined in the
aac2 (WB-12) strain carrying the AAC2, aac2Arg96His, or
aac2Arg252Gly alleles or the empty plasmid grown either at
28C or at 37C. The aac2Arg96His and aac2Arg252Gly muta-
tions determined a significant reduction in absorption
spectra at 37C (Figure 5B). We also measured respiratory
activity in the same transformants. At 37C, oxygen con-
sumption was decreased by 90% in both mutant strains
compared to the wild-type AAC2 strain (Figure 5C), in
agreement with the lowered level of cytochromes and the
growth phenotype on non-fermentable carbon sources.
To assess the ADP/ATP transport of the mutant car-
riers, transport assays were carried out for each mutation
in both the WB-12 and W303-1B backgrounds. The
p.Arg96His Aac2 mutant protein was expressed to a similar
level as wild-type AAC2 in the WB-12 strain, but the ADP
transport rate was only 60% of the wild-type (Figure 5D).
This impairment of transport in yeast is not as great as
for the human AAC1 p.Arg80His mutant expressed in the
bacterial system described earlier (Figure 4B, 24%), suggest-
ing a difference between the yeast and human proteins,
which are only 52% identical. No transport activity was
detected in the aac2Arg252Gly strain; however, this is likely
due to the very low expression of the p.Arg252Gly Aac2
mutant protein as previously discussed (Figure 5D). Trans-
port assays were also carried out with the wild-type and
mutant carriers in the W303-1B background. Although
the relative expression levels are not known, there seems
to be no significant negative dominance effect on trans-
port activity of the mutant proteins on the wild-type pro-
teins (Figure 5D), corrected for protein levels, in agreement
with earlier observations.53
AAC1 Alterations Cause a Dysregulation of
Mitochondrial Protein Content
We next assessed another mechanism by which the ge-
netic dominance of the de novo SLC25A4mutations could
be explained, given the lack of a dominant-negative effectThe Americby in vitro experiments on the transport activity in yeast.
A previous study modeling human mutation-associated
adPEO in yeast suggested that the mutated Aac2 misfolds
to place torsional stress on the mitochondrial inner
membrane, leading to dysregulation of inner membrane
proteins including loss of Oxa1p, a protein proposed to
chaperone the insertion of proteins into the inner mito-
chondrial membrane, and of Tim22, which is involved in
mitochondrial protein import.54 We assessed steady-state
levels of the human homologs OXA1L and TIMM22 in
skeletal muscle samples from affected individuals but in
contrast to the reports in yeast, OXA1L and TIMM22
were markedly increased in affected subjects relative to
control subjects (Figure 6), suggesting that the lower levels
of AAC1 in the affected individuals cannot be explained by
loss of the protein import machinery.Discussion
We describe seven subjects with de novo, heterozygous,
single-nucleotide substitutions in SLC25A4; four subjects
harbor a c.239G>A mutation predicted to substitute the
arginine at position 80 to a histidine and three further sub-
jects had a c.703C>G mutation predicted to substitute
arginine 235 for a glycine residue. All affected individuals
presented with severe congenital hypotonia and profound
muscle weakness necessitating artificial ventilation, and
several died in early infancy. Available muscle biopsies
from affected individuals revealed histopathological evi-
dence of mitochondrial myopathy and a severe combined
respiratory chain defect as a consequence of marked
depletion of mtDNA copy number (Table 1). The strik-
ing similarity in clinical phenotype across our cohort
and the fact that the c.239G>A (p.Arg80His) or the
c.703C>G (p.Arg235Gly) mutations have spontaneously
arisen strongly suggest pathogenicity. Furthermore, both
mutations affect highly conserved and functionally
important amino acid residues, associated with loss of
steady-state AAC1 levels in subjects’ skeletal muscle and
diminished ATP transport activity in vitro.
Mutations in SLC25A4 are well-recognized causes of
mitochondrial disease; dominantly inherited SLC25A4
mutations have been documented in cases of adPEO, anan Journal of Human Genetics 99, 860–876, October 6, 2016 871
adulthood-onset mitochondrial disorder characterized
by ptosis, restriction of eye movements, and
the accumulation of clonally expanded mtDNA dele-
tions in post-mitotic tissues on account of disordered
mtDNA maintenance.8–12 Additionally, recessively in-
herited SLC25A4mutations are known tocause a childhood
or early adulthood-onset mitochondrial myopathy and
cardiomyopathy phenotype with lactic acidosis and
proximal muscle weakness13–16 (summarized in Table S1).
The case subjects we present here, with de novo dominant
mutations, can be considered to show a third distinct clin-
ical phenotype associated with mutations in SLC25A4,
which is more severe in its clinical presentation than those
previously described.
Despite the findings of SLC25A4 mutations in adPEO
with multiple mtDNA deletions,8 the mechanism of how
an ADP/ATP carrier causes mtDNA instability is unknown.
Disorders of mtDNA maintenance are typically a conse-
quence of mutations in replicative enzymes or those
involved in nucleotide synthesis, leading to mtDNA deple-
tion in the case of severe enzyme defects and multiple
mtDNA deletions upon moderate defects.55 The current
finding of mtDNA depletion in early-onset cases with
SLC25A4mutations links this gene to the causes of typical
mtDNA maintenance disorders and strongly suggests that
the transporter dysfunction causes insufficient adenine
nucleotide availability for dATP synthesis and consequent
imbalanced dNTP pools, leading to mtDNA depletion.
There has been considerable debate as to whether
the dominant nature of SLC25A4 mutations associated
with adPEO is a consequence of dimerization of the car-
rier.35,56 The de novo mutations we present also behave
in a dominant manner, but both argue strongly against a
dimer model as explanation for the dominance, because
the affected residues point into the central cavity and
thus cannot be directly involved in dimerization. This
observation is consistent with studies carried out with
the yeast mitochondrial ADP/ATP carrier, which have
demonstrated that inactive carriers do not affect the func-
tion of active carriers.53 Mitochondrial ADP/ATP carriers
are structurally monomeric in the membrane57 and in
detergent,46,48 and they do not have a plausible dimeriza-
tion interface.48 The monomer has all of the functional
elements required for transport.44,58,59 One verified excep-
tion for mitochondrial carriers is the mitochondrial aspar-
tate/glutamate carrier, which dimerizes via its N-terminal
regulatory domain.60
In an attempt to explain the differences in clinical pre-
sentation associated with the various reported SLC25A4
mutations, we further analyzed the positions of affected
amino acid residues within the structure of AAC1. Late-
onset adPEO-associated mutations affect non-conserved
parts of the carrier that do not have an obvious function,
whereas the severe de novo mutations are both in highly
conserved, functionally important parts of the carrier
(Figure S3). Arg80 is contact point I in the proposed sub-
strate binding site of the carrier (Figure 3C) and Arg235872 The American Journal of Human Genetics 99, 860–876, Octoberforms one of the three salt bridge interactions required
for formation of the matrix network (Figure 3D), predict-
ing the de novo mutations to be more functionally detri-
mental to carrier function. Indeed, we have demonstrated
that recombinant AAC1-Arg80His or AAC1-Arg235Gly
mutants demonstrated severely impaired transport ability,
with residual transport rates of only 24% and 3%, res-
pectively (Figure 4B). The conservative p.Arg80His alter-
ation impairs substrate binding to a large degree because
histidine has a relatively short side chain and fewer
potential conformers compared to arginine (Figure 3C).
However, the large and flexible ADP molecule may adopt
a binding pose that would be able to span the contact
points of the substrate binding site, leading to a small
amount of transport activity. The p.Arg235Gly substitu-
tion resulted in a lower residual transport activity of 3%,
demonstrating the functional consequence of losing one
of the three salt bridge interactions of the matrix network.
The disruption and formation of the matrix network is a
key part of the alternating access transport mechanism of
AAC1.51
It is also interesting that residual transport activities
broadly fall into three groups that segregate with the clin-
ical phenotypes associated with differentmutations. Muta-
tions associated with adPEO manifested higher residual
transport activities (24%–56%) than the de novo muta-
tions, whereas the mutations associated with recessive
disease were completely null (<1% transport activity)
(Figure 4B). In the cases of the dominant mutations, the
severity of transport activity impairment correlates with
the severity of the clinical phenotypes. The majority of
adPEO-associated mutations showed approximately 50%
residual transport activity (Figure 4B). Assuming equal
expression of wild-type and mutant transporters, the total
flux across the innermembrane would bez75% compared
to healthy individuals. It is likely that there is spare capac-
ity in transport in order to deal with changes in bioener-
getic demand (e.g., rest versus exercise). In the case of the
de novo mutations, the mutant transporters have lower re-
sidual transport activities (3%–24%) (Figure 4B) and lower
expression levels (Figures 2A and 2C) resulting in an en-
ergy crisis, which in turn likely affects many other key
mitochondrial functions leading to the severe, early-onset,
and often fatal clinical presentations.
Reports of recessive SLC25A4mutations do not fit with a
correlation of AAC1 transport ability and clinical severity,
since the mutations (including nonsense,15,16 splicing,14
and missense13,16) are completely null but have a much
milder clinical phenotype than the case subjects presented
here (Tables 1 and S1).We confirmed that each of the reces-
sive missense mutations produce inactive transporters
(Figure 4B). In agreement, the affected residues are also
pointing inward and thus possibly interfere with key func-
tions of the carrier (Figure S3). Knockout mouse studies
have also shown that loss of AAC1 produces a similar
myopathy and cardiomyopathy phenotype to individ-
uals with recessive SLC25A4 mutations.61,62 We therefore6, 2016
postulate that the complete lack of functional AAC1 trig-
gers a compensatory mechanism to upregulate expression
of other isoforms of ADP/ATP carrier in cases of recessive
disease. There are four different AAC isoforms and at least
another three isoforms of the ATP-Mg/Pi carrier, which can
also transport ADP and ATP.63 All current information on
the relative expression levels in different tissues is based
on RNA studies.17 At present it is not possible to study
the relative expression of wild-type and mutant AAC1 at
the protein level nor are we able to distinguish between
each AAC isoform since the proteins are so similar
(>88% identity between AAC1, AAC2, and AAC3) that
the available antibodies recognize all isoforms.
The Arg252Gly mutant was expressed to very low levels
in yeast mitochondria (Figures 5C and 5D). This observa-
tion may indicate that residues of the matrix salt bridge
network might have additional functions in the biogen-
esis of the carrier, which could also explain the apparent
decrease in AAC1 protein levels seen in skeletal muscle
from subject 5 (Figure 2B). However, AAC1 protein levels
were also depleted in subject 1 (Figure 2A), but the expres-
sion of the equivalent Arg96His mutant in yeast was
comparable to wild-type Aac2 (Figures 5C and 5D). In
all tested subjects, residual AAC steady-state levels were
approximately 10%–30% (Figure 2), which is surprising
given the heterozygous nature of these mutations. We
investigated whether loss of AAC1 could be explained
by misfolding of the protein, which may exert torsional
stress on the mitochondrial inner membrane and disrupt
the function of other mitochondrial proteins, which has
been shown with mutations in yeast that model some
of the human mutations associated with adPEO.54 In
yeast strains expressing mutated Aac2, steady-state levels
of other inner membrane proteins such as Oxa1p and
Tim22 were decreased.54 Western blot analysis of subject
muscle tissue actually showed a marked increase in
OXA1L and TIMM22 protein levels (Figures 6A and 6B),
suggesting a different mechanism. However, the increase
in OXA1L relative to other inner mitochondrial mem-
brane proteins and the disorganized cristae observed by
electron microscopy in subject 3 (Figure S1) does suggest
that the AAC1 mutations, and the consequent effect on
expression levels, has a profound effect on inner mem-
brane content and structure. AAC1 is the most abundant
protein of the inner mitochondrial membrane in skeletal
muscle and disruption of its expression may explain the
observed morphological changes.
To summarize the clinical heterogeneity of SLC25A4mu-
tations, we hypothesize that adPEO mutations are less se-
vere due to the mutations affecting peripheral amino acids
of AAC1 not crucial for transport; recessively inheritedmu-
tations are null for AAC1 transport ability and another
transporter is likely upregulated to compensate; de novo
dominant mutations are the most clinically severe as
they affect amino acids in crucial functional domains
of AAC1, resulting in severely impaired transport ability
and a decrease in total AAC expression, thus ruling outThe Americcompensation from other isoforms possibly due to effects
on insertion and stability of the protein.
The recurrent nature of the de novo c.239G>A
(p.Arg80His) mutation is likely due to it being located
within a CpG dinucleotide, which is a known mutation
hotspot.64 Mutation rates at CpG sites are estimated
to be 18.2 times higher than at non-CpG sites due to spon-
taneous deamination of 5-methylcytosine nucleotides
to thymine.65 Most reports of recurrent de novo muta-
tions associated with disease occur in CpG sites causing
substitution of arginine residues.66–70 The c.703C>G
(p.Arg235Gly) mutation is not located at a CpG site, which
may explain the less frequent recurrence.
Importantly, the recurrent nature of these mutations
suggests that pathogenic de novo mutations may be far
more common causes of early-onset mitochondrial disease
than anticipated. Confirming the pathogenicity of these
de novo mutations has immense implications for the
application of WES, and the subsequent filtering of
sequence data, to the investigation of mitochondrial dis-
ease; all severe, early-onset Mendelian cases reported to
date show a recessive pattern of inheritance and as such
a recessive model of disease is prioritized in bioinformatic
pipelines. WES of family trios (parents and proband) al-
lows de novo mutations to be easily identified as candi-
dates for further functional studies. Our study underscores
the importance of sequencing trios: subjects 1, 6, and 7
were initially sequenced as singleton case subjects, remain-
ing unresolved until the subsequent identification of the
mutations as de novo and present in other affected indi-
viduals with identical clinical phenotypes.Accession Numbers
The ClinVar accession number for c.703C>G (p.Arg235Gly) is
SCV000297810 and for c.239G>A (p.Arg80His) is SCV000297809.Supplemental Data
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